|Description||Cediranib (AZD-2171; tentative trade name Recentin) is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.The drug is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.|
|Appearance||white solid powder|
|Synonyms||US brand name: Recentin. Foreign brand name: Recentin. Code name: AZD2171.AZD 2171; AZD-2171|
|Current Developer||AstraZeneca Pharmaceuticals LP.|
Ilorasertib, also know as ABT-348, is a novel, potent and orally bioavailable inhibitor of the Aurora kinases as well as the VEGF and PDGF families of receptor ...
SCR-1481B1, also known as c-Met inhibitor 2, is an effective inhibitor of MET kinase so that probably has anti-tumor activity. It is also found to be an inhibit...
Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respect...
Apatinib mesylate is an orally bioavailable, small-molecule receptor tyrosine kinase inhibitor with potential antiangiogenic and antineoplastic activities. Apa...
Telatinib is a potent inhibitor of VEGFR2/3, c-Kit and PDGFRα with IC50 of 6 nM/4 nM, 1 nM and 15 nM, respectively.
ZM306416 is a vascular endothelial growth factor receptor (VEGFR) antagonist.
Regorafenib monohydrate is a multitargetedinhibitor of tyrosine kinase with IC50 values of 13nM, 4.2nM, 46nM, 2.5nM, 28nM, 19nM, 202nM, 22nM, 7nM, 1.5nM and 311...
XL647 is an orally bioavailable small-molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. It inhibits EGFR, HER2, VEGFR and EphB...